The U.S. Food and Drug Administration has approved gene therapy for treating children with Spinal Mu
19 June 2020
The US FDA has approved Novartis to supply a gene therapy called Zolgensma, for treating spinal muscular atrophy (SMA). This treatment costs about $ 2.1 million. The treatment can completely cure SMA, but at the highest ever cost for gene therapy.
Help tools
Font size
A
A
A
-
Gray level -
High Definition -
Yellow letters -
Bright colors -
Underline Link -
Easy to read font -
Reset